Conduit Pharmaceuticals I... (CDT)
NASDAQ: CDT
· Real-Time Price · USD
1.54
-0.01 (-0.65%)
At close: Aug 21, 2025, 3:58 PM
1.52
-1.30%
After-hours: Aug 21, 2025, 06:50 PM EDT
Conduit Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Jun 29, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Revenue | n/a | n/a | n/a | 654.93M | n/a | 535.67M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 413.42M | 190K | 827.15M | 410.92M | 377.53M | 334.08M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 258.57M | -190K | 249.82M | 244M | -695.87M | 201.6M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -4.95M | -4.01M | -3.51M | -5.81M | -3.14M | -2.96M | -895K | -430K | -1.72M | -1.51M | -1.67M | -933K | -279K | -291K | -4.38K |
Interest Income | 4K | 8K | 2K | n/a | 2K | 9K | 30K | n/a | 275.29K | 664.23K | 1.16M | 609.92K | 191.59K | n/a | n/a |
Pretax Income | -6.03M | -5.15M | -2.41M | -6.46M | -5.38M | -3.55M | 1.78M | 2.63M | -1.73M | -1.67M | -3.07M | -956K | -87.83K | -307K | -4.38K |
Net Income | -6.03M | -5.15M | -2.41M | -6.46M | -5.38M | -3.57M | 1.78M | 1.99M | -1.73M | -1.67M | -3.07M | -956K | -118K | -307K | -4.38K |
Selling & General & Admin | 131.92M | 2.7M | 2.93M | 2.72M | 3.12M | 2.83M | 805K | 430K | 1.72M | 2.01M | 1.72M | 775K | 279.42K | 291K | 4.38K |
Research & Development | 33.94M | 1.31M | 132K | 3.09M | 25K | 128K | 90K | n/a | n/a | n/a | -47K | 158K | n/a | n/a | n/a |
Other Expenses | n/a | -190K | n/a | n/a | n/a | n/a | n/a | n/a | -23K | -280K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 165.86M | 3.82M | 3.06M | 5.81M | 3.14M | 2.96M | 895K | 430K | 888K | 1.51M | 1.67M | 933K | 279.42K | 291K | 4.38K |
Interest Expense | 57K | 176K | 960K | 310K | 119K | 119K | 330K | 47K | 39K | 5K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 829K | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.95M | 4.01M | 3.51M | 5.81M | 3.14M | 2.96M | 895K | 1.07M | 888K | 1.51M | 1.67M | 933K | 279.42K | 291K | 4.38K |
Income Tax Expense | n/a | n/a | 10K | n/a | n/a | n/a | n/a | n/a | 1K | n/a | n/a | n/a | 29.7K | n/a | n/a |
Shares Outstanding (Basic) | 39.51M | 2.01M | 2.03M | 2.18M | 1.85M | 1.85M | 1.85M | 32.7K | 36.21K | 36.21K | 432.15K | 1.81M | 432.15K | 36.21K | 432.13K |
Shares Outstanding (Diluted) | 40M | 2.04M | 2.06M | 2.18M | 1.85M | 1.85M | 1.99M | 1.65M | 36.21K | 36.21K | 432.15K | 1.81M | 432.15K | 36.21K | 432.13K |
EPS (Basic) | 1.54 | -1.32 | 3.88 | 1.32 | -109.33 | -72.15 | 0.96 | 89.44 | -47.8 | -46.2 | -7.2 | -26.4 | -0.27 | -8.4 | -0.01 |
EPS (Diluted) | 1.53 | -1.32 | -21.6 | 1.30 | -109.33 | -72.15 | -0.61 | 1.00 | -16 | -46.2 | -7.2 | -26.4 | -0.27 | -8.4 | -0.01 |
EBITDA | -5.14M | -4.78M | -994K | -6.29M | -5.26M | -2.96M | 1.9M | 1.99M | -1.69M | -1.67M | -1.34M | -956K | -87.83K | -254K | -4.38K |
EBIT | -5.97M | -4.97M | -1.45M | -6.29M | -5.26M | -3.43M | 1.9M | 2.63M | -1.69M | -1.67M | -1.34M | -956K | -87.83K | -307K | -4.38K |
Depreciation & Amortization | 828K | 190K | 452K | 5K | -26.99M | 26.99M | n/a | -39.59K | 122.08K | 41.58K | 54.88K | 27.08K | 86.06K | n/a | n/a |